{"id":4732,"date":"2026-05-19T10:02:34","date_gmt":"2026-05-19T10:02:34","guid":{"rendered":"https:\/\/news.gmj.ge\/?p=4732"},"modified":"2026-05-19T10:02:34","modified_gmt":"2026-05-19T10:02:34","slug":"overdiagnosis-melanoma-emotional-harm-screening","status":"publish","type":"post","link":"https:\/\/news.gmj.ge\/?p=4732","title":{"rendered":"The Hidden Harm of Overdiagnosis: Why Finding More Melanomas Doesn’t Save Lives"},"content":{"rendered":"

A diagnosis of melanoma in situ carries profound psychological consequences for patients, despite evidence that most cases are biologically indolent and will never progress to invasive disease. Research published in The BMJ<\/a> reveals that the dramatic rise in melanoma incidence over the past two decades is largely a marker of increased diagnostic scrutiny rather than a true epidemic of dangerous skin cancer\u2014a phenomenon known as overdiagnosis that is reshaping dermatology practice and patient wellbeing across developed nations.<\/p>\n

\n
15 years<\/div>\n
Period over which patients diagnosed with melanoma in situ show an overall reduced risk of death from any cause, according to research cited in The BMJ<\/a><\/div>\n<\/div>\n
\n

The Overdiagnosis Pattern: Rising In Situ Cases Without Corresponding Increase in Invasive Melanomas<\/h4>\n
\n
\n
Melanoma In Situ<\/div>\n
Dramatic Rise<\/div>\n
Incidence has increased substantially over past 20 years, driven by increased screening and diagnostic scrutiny<\/div>\n<\/div>\n
\n
Invasive Melanomas<\/div>\n
No Corresponding Fall<\/div>\n
Absence of decline in invasive cases is the hallmark of overdiagnosis, indicating detection of indolent lesions<\/div>\n<\/div>\n<\/div>\n

Source: The BMJ, Davies commentary | Georgian Medical Journal News<\/p>\n<\/div>\n

The Paradox of Increased Detection Without Improved Outcomes<\/h2>\n

The core issue underlying melanoma overdiagnosis lies in a fundamental epidemiological paradox: as diagnostic capability and awareness expand, detection of in situ melanomas has surged, yet rates of invasive melanoma\u2014the form that poses genuine mortality risk\u2014have remained flat or declined only modestly. According to commentary published in The BMJ<\/a>, this absence of a corresponding fall in invasive melanomas is the defining hallmark of overdiagnosis, indicating that many lesions detected would never have progressed to clinically significant disease.<\/p>\n

Most melanoma in situ cases are biologically indolent, meaning they grow slowly or not at all and pose minimal threat to patient survival. Yet the diagnosis itself\u2014regardless of the actual biological behaviour of the lesion\u2014triggers substantial psychological distress. Patients receiving a melanoma diagnosis often experience anxiety, fear of recurrence, and ongoing surveillance burden, even when their prognosis is exceptionally favourable. The emotional cost of overdiagnosis extends beyond the individual to families and healthcare systems, consuming resources and psychological capital without corresponding mortality benefit.<\/p>\n

Why Screening Systems Amplify the Problem<\/h2>\n

Multiple structural forces have conspired to drive melanoma overdiagnosis in dermatology. Social media messaging promoting skin cancer awareness, government cancer targets that incentivise melanoma detection, and the proliferation of for-profit “mole screening” shops in high streets have all contributed to a culture of diagnostic intensity that may exceed what population health evidence supports. According to The BMJ<\/a>, these commercial and policy drivers exist despite the absence of evidence that undirected mole screening reduces melanoma mortality in asymptomatic populations.<\/p>\n

The problem is particularly acute because melanoma screening, unlike screening programmes for other cancers<\/a>, lacks robust evidence of benefit in unselected populations. When screening is universal and unguided, the ratio of harm to benefit increases substantially. Patients with atypical moles or family history benefit from dermoscopic surveillance; the general public does not. Yet commercial screening venues and social media campaigns make no such distinction, transforming healthy individuals into patients with diagnoses they may not require.<\/p>\n

The Reassuring Evidence Hidden Within the Harm<\/h2>\n
\n

A diagnosis of melanoma in situ is associated with an overall reduced risk of death from any cause over 15 years after diagnosis, greatly exceeding any exceedingly small risk of death from melanoma itself.<\/p>\n

\u2014 Commentary, The BMJ<\/a>, 2024<\/cite><\/p><\/blockquote>\n

One critical piece of evidence offers reassurance to those who have received a melanoma in situ diagnosis: long-term follow-up data show that these patients experience better overall survival than the general population. This counterintuitive finding reflects the “healthy volunteer effect”\u2014people diagnosed with in situ melanoma are typically more engaged with healthcare, follow medical advice more reliably, and have greater health awareness than average. Their reduced mortality from all causes outweighs any theoretical risk from the melanoma itself.<\/p>\n

This evidence, highlighted in recent BMJ<\/a> commentary, should provide genuine reassurance to the many patients living with melanoma in situ diagnoses. The diagnosis, while emotionally burdensome, does not appear to increase mortality risk. Yet the psychological harm of the diagnosis itself\u2014the fear, the surveillance appointments, the identity shift to “cancer patient”\u2014remains real and deserves recognition as a legitimate adverse effect of overdiagnosis. Clinicians and patients must weigh this emotional cost against the minimal mortality benefit of detecting lesions that would never have caused harm.<\/p>\n

Toward Evidence-Based Screening and Informed Decision-Making<\/h2>\n

The emerging recognition of melanoma overdiagnosis as a major problem in dermatology signals a shift toward more evidence-based, risk-stratified approaches to screening and surveillance. Rather than population-wide mole screening, guidelines should emphasize targeted surveillance for high-risk patients: those with a personal or family history of melanoma, atypical mole syndrome, or fair skin with extensive sun exposure. Unselected screening in asymptomatic individuals with no risk factors remains difficult to justify on mortality grounds, despite its commercial appeal.<\/p>\n

Clinicians have a duty to discuss the harms of screening alongside benefits\u2014a conversation often absent from marketing-driven initiatives. Patients deserve to understand that finding a melanoma in situ may not improve their survival, that living with that diagnosis carries emotional costs, and that surveillance itself carries burdens<\/a> that may exceed the risk being monitored. Informed consent for screening should be explicit: patients should choose surveillance, not have it imposed by commercial messaging or incidental findings.<\/p>\n

The path forward requires re-calibration of melanoma awareness campaigns to emphasize clinical concern signs rather than generic “see a dermatologist,” stricter regulation of commercial mole screening to ensure appropriate patient selection, and integration of shared decision-making into dermoscopy and biopsy practice. Dermatology must move from a model of maximal detection toward one of optimal detection\u2014distinguishing lesions that pose genuine risk from the many indolent changes that do not require diagnosis or surveillance.<\/p>\n

\n

Key takeaways<\/h3>\n